Welcome to our dedicated page for Innate Pharma S.A. news (Ticker: $IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innate Pharma S.A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innate Pharma S.A.'s position in the market.
Innate Pharma announced that four of its drug candidate abstracts have been accepted for presentation at the EHA 2024 Congress in Madrid, from June 13-16, 2024. Two abstracts focus on SAR443579 (IPH6101), an anti-CD123 NK cell engager developed with Sanofi, being tested in a Phase 1/2 trial for blood cancers. The other two abstracts highlight IPH6501, aimed at treating relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma, also in Phase 1/2 trials. Chief Medical Officer Dr. Sonia Quaratino underscored the potential benefits of these NK cell engagers for patients with high unmet medical needs.
Innate Pharma (NASDAQ: IPHA) released its Q1 2024 business update, highlighting key developments in its clinical pipeline and financial performance. The company presented preclinical data for IPH45, an anti-Nectin-4 ADC, at AACR 2024 and advanced IPH6501, its second-generation ANKET®, into clinical development for NHL. Partner Sanofi progressed SAR443579/IPH6101 to Phase 2 in blood cancers. For Q1 2024, Innate reported revenues of €6.6 million, down from €26 million in Q1 2023. The company's cash position stood at €113.9 million as of March 31, 2024, excluding a pending €4 million milestone payment from Sanofi. Innate anticipates a cash runway until the end of 2025. Multiple presentations at ASCO 2024, including results from the TELLOMAK Phase 2 trial for lacutamab, are scheduled. The FDA lifted a partial clinical hold on lacutamab's IND in January 2024. A conference call to discuss these results will be held today.
Innate Pharma SA has scheduled a conference call and webcast on May 14, 2024, to discuss the business progress during the first quarter of 2024. Key executives will provide updates on the company's performance and future plans.